Janney Montgomery Scott LLC Lowers Holdings in Bausch Health Companies Inc (BHC)

Janney Montgomery Scott LLC lowered its holdings in shares of Bausch Health Companies Inc (NYSE:BHC) by 6.1% in the 1st quarter, Holdings Channel reports. The firm owned 26,239 shares of the company’s stock after selling 1,700 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Bausch Health Companies were worth $648,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in BHC. Bessemer Group Inc. bought a new position in Bausch Health Companies during the fourth quarter valued at $33,000. Beutel Goodman & Co Ltd. bought a new position in Bausch Health Companies during the first quarter valued at $38,000. Lindbrook Capital LLC bought a new position in Bausch Health Companies during the fourth quarter valued at $41,000. Winslow Evans & Crocker Inc. lifted its position in Bausch Health Companies by 43.5% during the first quarter. Winslow Evans & Crocker Inc. now owns 3,300 shares of the company’s stock valued at $82,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Valeo Financial Advisors LLC lifted its position in Bausch Health Companies by 1,795.6% during the first quarter. Valeo Financial Advisors LLC now owns 3,431 shares of the company’s stock valued at $85,000 after purchasing an additional 3,250 shares during the last quarter. Institutional investors and hedge funds own 54.30% of the company’s stock.

Several research firms have recently issued reports on BHC. HC Wainwright restated a “buy” rating on shares of Bausch Health Companies in a report on Thursday, February 28th. Zacks Investment Research upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a report on Thursday, February 14th. SunTrust Banks began coverage on shares of Bausch Health Companies in a report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 target price for the company. Mizuho raised their target price on shares of Bausch Health Companies from $39.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Finally, Piper Jaffray Companies set a $28.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $27.99.

In related news, CEO Joseph C. Papa purchased 30,000 shares of Bausch Health Companies stock in a transaction that occurred on Thursday, February 28th. The shares were bought at an average price of $23.67 per share, with a total value of $710,100.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 11.87% of the company’s stock.

Bausch Health Companies stock opened at $24.44 on Thursday. The stock has a market capitalization of $8.62 billion, a PE ratio of 6.08, a PEG ratio of 0.56 and a beta of 0.55. The company has a debt-to-equity ratio of 8.61, a current ratio of 1.08 and a quick ratio of 0.83. Bausch Health Companies Inc has a 12-month low of $17.20 and a 12-month high of $28.45.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings results on Monday, May 6th. The company reported $1.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.89 by $0.14. The company had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.03 billion. Bausch Health Companies had a negative net margin of 19.27% and a positive return on equity of 47.01%. The firm’s revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.89 EPS. Research analysts forecast that Bausch Health Companies Inc will post 4.15 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Janney Montgomery Scott LLC Lowers Holdings in Bausch Health Companies Inc (BHC)” was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.themarketsdaily.com/2019/05/23/janney-montgomery-scott-llc-lowers-holdings-in-bausch-health-companies-inc-bhc.html.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

See Also: Capital Gains

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.